Abstract
We conducted a systematic review (PROSPERO CRD42023393345) of severe acute respiratory syndrome (SARS) transmission models and parameters characterising its transmission, evolution, natural history, severity, risk factors and seroprevalence. Information was extracted using a custom database and quality assessment tool.
We extracted 519 parameters, 243 risk factors, and 112 models from 288 papers. Our analyses show SARS is characterised by high lethality (case fatality ratio 10.9%), transmissibility (R0 range 1.1-4.59), and is prone to superspreading (20% top infectors causing up to 91% of infections). Infection risk was highest among healthcare workers and close contacts of infected individuals. Severe disease and death were associated with age and existing comorbidities. SARS’s natural history is poorly characterised, except for the incubation period and mean onset-to-hospitalisation.
Our associated R package, epireview, contains this database, which can continue to be updated to maintain a living review of SARS epidemiology and models, thus providing a key resource for informing response to future coronavirus outbreaks.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
All authors acknowledge funding from the Medical Research Council (MRC) Centre for Global Infectious Disease Analysis (MR/X020258/1) funded by the UK MRC and carried out in the frame of the Global Health EDCTP3 Joint Undertaking supported by the EU; the NIHR for support for the Health Research Protection Unit in Modelling and Health Economics, a partnership between the UK Health Security Agency (UKHSA), Imperial College London, and London School of Hygiene & Tropical Medicine (grant code NIHR200908). AC was supported by the Academy of Medical Sciences Springboard scheme, funded by the Academy of Medical Sciences, the Wellcome Trust, the UK Department for Business, Energy, and Industrial Strategy, the British Heart Foundation, and Diabetes UK (reference SBF005\1044) and acknowledges research funding from the Sergei Brin foundation. CM acknowledges the Schmidt Foundation for research funding (grant code 62263345). PD, TN, KP acknowledge funding from Community Jameel. RJ acknowledges funding from CEPI. GCD acknowledges funding from the Royal Society. KD acknowledges research funding from the Wellcome Trust (220885/Z/20/Z). RKN acknowledges research funding from the MRC Doctoral Training Partnership (grant MR/N014103/1). KM acknowledges research funding from the Imperial College Presidents PhD Scholarship. The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. For the purpose of open access, the author has applied a Creative Commons Attribution (CC BY) licence to any Author Accepted Manuscript version arising from this submission.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The code and data availability is available at https://github.com/mrc-ide/epireview and https://github.com/mrc-ide/priority-pathogens
https://github.com/mrc-ide/epireview
https://github.com/mrc-ide/priority-pathogens
https://mrc-ide.github.io/priority-pathogens/articles/pathogen_sars.html